Research Applications
Selective anticancer therapy. HDM-2-positive tumors. Pancreatic cancer research. Combination with conventional chemotherapy.
Mechanism of Action
PNC-27 binds to HDM-2 overexpressed on cancer cell surfaces. The MRR domain anchors in the membrane, while the p53 domain binds HDM-2, causing peptide oligomerization and membrane pore formation. This induces rapid necrotic cell death specific to HDM-2-expressing cancer cells.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsResearch Studies
Frequently Asked Questions
PNC-27 is a synthetic peptide consisting of an HDM-2 (human double minute-2) binding domain from the p53 tumor suppressor protein fused to a cell-penetrating membrane residency peptide (MRR). It was designed to selectively kill cancer cells by targeting the HDM-2 protein — which is overexpressed on cancer cell membranes but absent from normal cell surfaces. PNC-27 binds to surface-expressed HDM-2, forming pores in cancer cell membranes and inducing cell death through necrosis rather than apoptosis. Preclinical studies show selective cytotoxicity against pancreatic, breast, and leukemia cancer cells while sparing normal cells.
PNC-27 binds to HDM-2 overexpressed on cancer cell surfaces. The MRR domain anchors in the membrane, while the p53 domain binds HDM-2, causing peptide oligomerization and membrane pore formation. This induces rapid necrotic cell death specific to HDM-2-expressing cancer cells.
Selective anticancer therapy. HDM-2-positive tumors. Pancreatic cancer research. Combination with conventional chemotherapy.
